末梢神経障害(感覚性ニューロパチー)(Peripheral Neuropathy)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peripheral Neuropathy (Sensory Neuropathy) Overview 8
Therapeutics Development 9
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) – Overview 9
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) – Comparative Analysis 10
Peripheral Neuropathy (Sensory Neuropathy) – Therapeutics under Development by Companies 11
Peripheral Neuropathy (Sensory Neuropathy) – Therapeutics under Investigation by Universities/Institutes 13
Peripheral Neuropathy (Sensory Neuropathy) – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Peripheral Neuropathy (Sensory Neuropathy) – Products under Development by Companies 17
Peripheral Neuropathy (Sensory Neuropathy) – Products under Investigation by Universities/Institutes 18
Peripheral Neuropathy (Sensory Neuropathy) – Companies Involved in Therapeutics Development 19
Acorda Therapeutics, Inc. 19
aTyr Pharma, Inc. 20
GeNeuro SA 21
INSYS Therapeutics, Inc. 22
Mitsubishi Tanabe Pharma Corporation 23
Neuren Pharmaceuticals Limited 24
Pfizer Inc. 25
RegeneRx Biopharmaceuticals, Inc. 26
Takeda Pharmaceutical Company Limited 27
Teijin Pharma Limited 28
Peripheral Neuropathy (Sensory Neuropathy) – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
cannabidiol – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
fingolimod hydrochloride – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GL-2045 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
immune globulin (human) – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
immune globulin (human) – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Monoclonal Antibody for CIDP – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NNZ-2591 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NP-1998 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
NRP-2945 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Peptides for Neuropathic Pain and Peripheral Neuropathy – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
RGN-352 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Synthetic Peptides for Peripheral Neuropathy – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Peripheral Neuropathy (Sensory Neuropathy) – Recent Pipeline Updates 62
Peripheral Neuropathy (Sensory Neuropathy) – Dormant Projects 72
Peripheral Neuropathy (Sensory Neuropathy) – Discontinued Products 73
Peripheral Neuropathy (Sensory Neuropathy) – Product Development Milestones 74
Featured News & Press Releases 74
Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76